Fecal microbiome of monkeys on a high-fat diet and treated with an antisense oligonucleotide for inducible degrader of LDLR and a liver X receptor agonist

The Lipid Homeostasis study used a high-fat diet with low cholesterol (0.05% w/w or 0.12 mg/kcal) (HFD-MC) for the duration of the study, but it also included ASOs for IDOL and LXR agonist. LXR agonist treatment of the NHPs increased LDL cholesterol due to increased hepatic IDOL and consequent degradation of LDL receptor protein. Treatment with the IDOL ASO resulted in partial knockdown of the expression of IDOL in the liver and significantly blunted the LXR agonist-mediated increase in LDL cholesterol